Wellbutrin XL (bupropion) to PREVENT depression in patients with seasonal affective disorder (SAD)

Glaxo will be promoting Wellbutrin XL (bupropion) to PREVENT depression in patients with seasonal affective disorder (SAD).

It's the first drug approved for this use.

Up to 10% of people at northern latitudes get depressed in the fall and winter. It's thought that shorter days trigger changes in melatonin, serotonin, and other neurotransmitters.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote